Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2024-08-14 00:00:00 ET · period of report 2024-08-12 · accession 0001415889-24-021305 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-08-14 | 2024-08-12+ | HALO | Posard Matthew L. | Dir | S - Sale | $56.53 | -29.9K | 89.8K | -25% | -$1.69M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-13 | S | D | 10,000 | $56.19 | 79,755 | D | — | — | (F3) Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.058 to $56.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F2) Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director. |
| 2 | Common | Common Stock | 2024-08-14 | S | D | 9,881 | $57.70 | 69,874 | D | — | — | (F2) Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director. |
| 3 | Common | Common Stock | 2024-08-12 | S | D | 10,000 | $55.72 | 89,755 | D | — | — | (F1) Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.825. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F2) Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director. |